|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand显示文摘AIM: The role of hepatitis B virus (HBV) genotypes on the clinical features and prognosis of patients with hepatocellular carcinoma (HCC) is currently unknown. The aim of the present study was to evaluate the distribution of HBV genotypes and their clinical relevance in Thai patients.METHODS: HBV genotypes were determined by PCR-RFLP in stored sera of 93 asymptomatic carriers, 103 patients with chronic hepatitis, 60 patients with cirrhosis and 76patients with HCC. The clinical data were analyzed in relation to the HBV genotype.RESULTS: HBV genotypes C and B were predominant in Thailand, accounting for 73% and 21%, respectively. The distributions of genotypes B and C were similar in HCC patients compared to the other groups. Genotype C was significantly more common in HCC patients who were under 40 years old than genotype B (18% vs 0%, P= 0.03), but was significantly less common in patients older than 60 years (26% vs 56.5%, P= 0.01). The positive rate of hepatitis B e antigen (HBeAg) in patients with genotype C was significantly higher than that in patients with genotype B (71.6% vs 44.4%, P = 0.03 in chronic hepatitis; 56.8% vs 11.1%,P = 0.01 in cirrhosis). There were no differences between HCC patients with genotypes B and C regarding tumor staging by CLIP criteria and the overall median survival. Multivariate analyses showed that HBV genotype was not an independent prognostic factor of survival in HCC patients.CONCLUSION: Patients with genotype C had a higher positive rate of HBeAg and exhibited earlier progression of cirrhosis and HCC than those with genotype B. However,there were no differences in the risk of developing HCC and its prognosis between patients with these genotypes. | Pisit Tangkijvanich Varocha Mahachai Piyawat Komolmit Juthatip Fongsarun Apiradee Theamboonlers Yong Poovorawan | 2005 | World Journal of Gastroenterology2005，11，15： | 17 |
| 2 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 4 |
| 3 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 2 |
| 4 | Clinical and virological differences between hepatitis B virus genotypes B and C:a case-control study显示文摘 | Tangkijvanich P Mahachai V Komolmit P | 2004 | Med Assoc Thai2004，87，2： | 1 |
| 5 | Comparison between quantitative hepatitis B surface antigen, hepatitis B eantigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-a-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B 显示文摘 | Tangkijvanich P Komolmit P Mahachai V Sa-Nguanmoo P Theamboonlers A Poovorawan Y | 2010 | Heoatol Res2010，40，4： | 1 |
| 6 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
| 7 | Comparison between quantitative hepatitis B surface antigen,hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferonα-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B显示文摘 | Tangkijvanich P Komolmit P Mahachai V Sa-Nguanmoo P Theamboonlers A Poovorawan Y | | Hepatology Research0，，： | 1 |
| 8 | Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis显示文摘BACKGROUND The albumin-bilirubin(ALBI)score is an index of liver function recently developed to assess prognosis in patients with hepatocellular carcinoma(HCC).It can detect small changes in liver dysfunction and has been successfully applied to the prediction of survival in patients with non-malignant liver diseases of various etiologies.AIM To investigate the ALBI score for identifying decompensation risk at the 3-year follow-up in patients with compensated cirrhosis.METHODS One-hundred and twenty-three patients with compensated cirrhosis without HCC in King Chulalongkorn Memorial Hospital diagnosed by imaging were retrospectively enrolled from January 2016 to December 2020.A total of 113 patients(91.9%)had Child A cirrhosis with a median model for end-stage liver disease(MELD)score of less than 9.Baseline clinical and laboratory variables and decompensation events were collected.The ALBI score was calculated and validated to classify decompensation risk into low-,middle-,and high-risk groups using three ALBI grade ranges(ALBI grade 1:≤-2.60;grade 2:>-2.60 but≤-1.39;grade 3:>-1.39).Decompensation events were defined as ascites development,variceal bleeding,or grade 3 or 4 hepatic encephalopathy.RESULTS Among 123 cirrhotic patients enrolled,13.8%(n=17)developed decompensating events at a median time of 25[95%confidence interval(CI):17-31]mo.Median baseline ALBI score in compensated cirrhosis was significantly lower than that of patients who developed decompensation events[-2.768(-2.956 to-2.453)vs-2.007(-2.533 to-1.537);P=0.01].Analysis of decompensation risk at 3 years showed that ALBI score had a time-dependent area under the curve(tAUC)of 0.86(95%CI:0.78-0.92),which was significantly better than that of ALBI-Fibrosis-4(ALBI-FIB4)score(tAUC=0.77),MELD score(tAUC=0.66),Child-Pugh score(tAUC=0.65),and FIB-4 score(tAUC=0.48)(P<0.05 for all).The 3-year cumulative incidence of decompensation was 3.1%,22.6%,and 50%in the low-,middle-,and high-risk groups,respectively(P<0.001).The odds ratio for decompensation in patients of the high-risk group was 23.33(95%CI:3.88-140.12,P=0.001).CONCLUSION The ALBI score accurately identifies decompensation risk at the 3-year follow-up in patients with compensated cirrhosis.Those cirrhotic patients with a high-risk grade of ALBI score showed a 23 times greater odds of decompensation. | Huttakan Navadurong Kessarin Thanapirom Salisa Wejnaruemarn Thaninee Prasoppokakorn Roongruedee Chaiteerakij Piyawat Komolmit Sombat Treeprasertsuk | 2023 | World Journal of Gastroenterology2023，29，32： | 1 |
| 9 | Comparisonbetween quantitative hepatitis B surface antigen, hepatitis B eantigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B 显示文摘 | Tangkijvanich P Komolmit P Mahachai V | 2010 | Hepatol Res2010，40，4： | 1 |
| 10 | Co- mparison between quantitative hepatitis B surface an- tigen,hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis P, e-antigen- positive chronic hepatitis B显示文摘 | Tangkijvanich P Komolmit P Mahachai V | 2010 | Hepatol Res2010，40，4： | 1 |
| 11 | Compar-ison between quantitative hepatitis B surface antigen,hep-atitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B显示文摘 | Tangkijvanich P Komolmit P Mahachai V | | 0，，03： | 1 |
| 12 | Com- parison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-a- 2b therapy in hepatitis B e-antigen-positive chronic hep- atitis B 显示文摘 | Tangkijvanich P Komolmit P MahachaiV et al | 2010 | Hepatol Res2010，40，4： | 1 |
| 13 | Comparison between quantitative hepatitis B surface antigen,hepatitis B eantigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2btherapy in hepatitis B e-antigen-positive chronic hepatitis B显示文摘 | Tangki jvanich P Komolmit P Mahachai V | 2010 | Hepatol Res2010，40，4： | 1 |
| 14 | Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B显示文摘 | Pisit Tangkijvanich Piyawat Komolmit Varocha Mahachai Pattaratida Sa-nguanmoo Apiradee Theamboonlers Yong Poovorawan | 2009 | Journal of Clinical Virology2009，，2： | 1 |
| 15 | He- patic cytochrome p450 2el activity in nonalcoholic fatty liver disease显示文摘 | Prompila N Wittayalertpanya S Komolmit P | 2008 | J Med Assoc Thai2008，91，5： | 1 |
| 16 | Low pretreatment serum HBsAg level and viral mutations as predic- tors of response to PEG -interferon alpha -2b therapy in chron- ic hepatitis B显示文摘 | TANGKIJVANICH P KOMOLMIT P MAHACHAI V | 2009 | J Clin Virol2009，46，2： | 1 |
| 17 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
| 18 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
| 19 | Comparison be- tween quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitisB virus DNA levels for predicting virological response to pegylated tnterferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B显示文摘 | Tangkijvanich P Komolmit P Mahachai V | 2010 | Hepatol Res2010，40，4： | 1 |
| 20 | Intrahepatic HBV DNA and covalently closed circular DNA (cecDNA) levels in patients positive for anti-HBc and negative for HBsAg显示文摘 | Chaiteerakij R Komolmit P Sa-nguanmoo P | 2010 | Southeast Asian J Trop Med Public Health2010，41，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员